Buy this article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.



July 2004, Volume 34 Number 7 , p 26 - 27



© 2004 Lippincott Williams & Wilkins, Inc. Volume 34(7)             July 2004             p 26–27 Inhaled antirejection drug shows promise [DRUG NEWS: LUNG TRANSPLANTS]

Lung transplant recipients who inhale an antirejection drug may increase their chances of survival fourfold, according to a new study. Patients undergoing this new, organ-specific approach to antirejection therapy inhale an experimental version of cyclosporine. Delivered directly to the lungs, the drug appears to stop immune cells from attacking vulnerable transplanted tissue.

In a study of 56 new lung recipients, half received the inhaled form of cyclosporine and half received a placebo inhalant. All patients used their inhalant 3 days a week for 2 years following their transplant. Patients in both groups also received standard antirejection therapy.

Researchers followed patients for 2 to 5 years after their transplant. ...

To continue reading, buy this article for just $3.95.

Have a coupon or promotional code? Enter it here: